Introduction
Pyrimidines represent an important group of heterocyclic compounds exhibiting a broad spectrum of biological activity. [1] [2] [3] [4] [5] The pyrimidine moiety is a building block for new drugs coming to market almost every year. As examples, compounds for the treatment of metastatic BRAF-mutant melanoma (Dadrafenib mesylate) or the cure of pulmonary arterial hypertension (Macitentan and Riociguat) contain the pyrimidine ring. 6 5-Nitrosopyrimidines, and their complexes with platinum, palladium, rhodium and iridium have been shown to exhibit antifungal, 7 antimicrobial, 8 and antiproliferative activity, 9, 10 and it is known that 4,6-disubstituted-5-nitrosopyrimidines possess CDK1-and CDK2-inhibitory activity. [11] [12] [13] [14] Recently, we have found that some 4,6-diamino-substituted-5-nitrosopyrimidines are able to inhibit growth of solid tumors from human cancer cell lines with GI 50 values in the ranges 3.1-7.2 μM, but do not cause apoptosis. 15 5-Nitrosopyrimidines are useful intermediates for the preparation of various condensed pyrimidine derivatives, 7, 16, 17 so they can be useful as building blocks in organic synthesis. 5-Nitrosopyrimidines with an electron-donating group at position 2 are usually prepared by direct nitrosation of the corresponding pyrimidines with sodium nitrite in aqueous acid or with isopentyl nitrite under neutral conditions. 7, 13, [17] [18] [19] [20] Some time ago, we found that 2-unsubstituted-5-nitrosopyrimidines (2) can be prepared also via intramolecular oxidation-reduction reactions of methyl-N-methyl-N-(5-nitro-6-substituted pyrimidin-4-yl)glycinates (1) in basic media. Some by-products (pteridines 3 and purine derivatives 4 and 5) can also be formed in these reactions as shown in Scheme 1. 15, 21, 22 In our previous work, 22 we have found that the outcomes of these transformations depend strongly on the nature of the substituent R at position 6 of the pyrimidine ring. Thus, methyl-N-methyl-N-(5-nitropyrimidin-4-yl)glycinates bearing amino and arylamino groups at the pyrimidine position 6, on reaction with alkoxides, are converted into the corresponding 6-substituted 4-methylamino-5-nitrosopyrimidines. Their reactions with sodium alkoxides, on the other hand, yield mixtures of 6-alkylamino-4-methylamino-5-nitrosopyrimidines (2) and 5-hydroxy-8-methyl-5,8-dihydropteridine-6,7-diones (3). Finally, after similar treatment, methyl N-(6-dialkylamino-5-nitropyrimidin-4-yl)-N-methylglycinates are converted into the corresponding 6-dialkylamino-9-methylpurin-8-ones (4) and 8-alkoxy-6-dialkylamino-9-methylpurines (5) . Therefore, with the aim of extending the scope of this method to prepare a greater variety of substituted nitrosopyrimidines, a number of ethyl-N-alkyl-N-(6-arylamino-5-nitropyrimidin-4-yl)glycinates (11) (12) (13) (14) were synthesized, and subjected to the intramolecular oxidation-reduction reactions as shown in Scheme 2.
The starting compound 4,6-dichloro-5-nitropyrimidine (6) was treated with an equivalent amount of an ethyl N-alkylglycinate in the presence of triethylamine at room temperature (Scheme 2). This nucleophilic substitution reaction resulted in formation of ethyl-N-(6-chloro-5-nitropyrimidin-4-yl)-N-substituted glycinate compounds (7) (8) (9) (10) in 75-89% yields. In all cases, the substitution reactions were completed within 30 minutes. Next, compounds 7-10 were reacted with various arylamines in the presence of triethylamine under reflux in methanol or ethanol for 1 h to form the corresponding ethyl-N-alkyl-N-(6-arylamino-5-nitropyrimidin-4-yl)glycinates (11) (12) (13) (14) in 43-96% yields. This second substitution depends on the electronic effects of the substituent on the arylamines. Electron-rich arylamines reacted with compounds 7-10 smoothly on reflux in methanol. For substitution of the second chlorine by 3-trifluoromethylaniline, however, refluxing at the slightly higher boiling-point temperature of ethanol was required. TEA / DCM R = isopropyl (7, 11a-f, 15a-e, 19f); cyclopropyl (8, 12a-f, 16a-f, 20c, 20e, 20f, 23a, 23c, 23e); cyclopentyl (9, 13a-f, 17a-f, 21f); cyclohexyl (10, 14a-f, 18a-f, 22f 
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+ + Scheme 2. Synthesis of ethyl N-alkyl-N- (6-arylamino-5-nitropyrimidin-4-yl) glycinates (11) (12) (13) (14) and their reactions with sodium methoxide.
With the ethyl-N-alkyl-N-(6-arylamino-5-nitropyrimidin-4-yl)glycinates (11) (12) (13) (14) in hand, we investigated their intramolecular oxidation-reduction reactions by treatment with an equivalent of sodium methoxide in methanol at room temperature. 4-Alkylamino-6-arylamino-5-nitrosopyrimidines (15) (16) (17) (18) were the major products of these reactions (Table 1) . In a number of cases, however, along with compounds 15-18, the formation of 5-hydroxypteridine-6,7-diones (19) (20) (21) (22) and/or trans-esterification methyl-esters products (23), were observed. From the data presented in Table 1 , it is clear that pteridines 19-22 are formed as secondary products when starting esters 11-14 have electron-withdrawing groups in the 6-position of the pyrimidine ring. The transesterification products 23 were formed only from ethyl-N-cyclopropyl-N-(6-arylamino-5-nitropyrimidin-4-yl)glycinates (12) . 
Mechanistically, the intramolecular oxidation-reduction reactions of N-substituted-N-(5-nitropyrimidin-4-yl)glycinates start from the base-induced electrocyclic ring closure of the aci-forms of glycinates 11-14 as shown in Scheme 3. Next, there are two oxadiazine ring-cleavage pathways. Pathway a leads to elimination of the CHO-CO 2 C 2 H 5 molecule, and the formation of the desired 5-nitrosopyrimidines 15-18. When the arylamino group in the 6-position of the pyrimidine moiety has electron-withdrawing groups, however, cleavage can proceed partially via pathway b, followed by recyclization to pteridinones 19-22. Additionally, we believe that the strained cyclopropane ring in N-cyclopropyl-N- (6-arylamino-5-nitropyrimidin-4-yl) glycinates (12) is destabilizing the aci-form; therefore, some side transesterification reactions can occur. This hypothesis is supported by the comparison of UV/Vis spectra of N-isopropyl-N- [6-(4-propyloxyphenyl) arylamino-5-nitropyrimidin-4-yl]glycinate (11c) and N-cyclopropyl-N- [6-(4-propyloxyphenyl) arylamino-5-nitropyrimidin-4-yl]glycinate (12c) (Figure 1 ). As can be seen from the spectra, the N-isopropyl derivative 11c has absorption The synthesized products 15-23 were characterized by spectroscopic methods. In the NMR spectra of 5-nitrosopyrimidines (15) (16) (17) (18) , two sets of signals were observed. As is known from previous studies, 21 ,23 the nitroso-group in 5-nitrosopyrimidines with amino substituents in the neighboring 4-and 6-positions can form stable intramolecular hydrogen bonds; therefore, two rotamers (I and II) are possible (Scheme 4). M. Dračinsky and co-authors explained this structural behavior of nitrosopyrimidines. 
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Scheme 4. Proposed rotamer formation from intramolecular hydrogen bonding between nitroso-group in 5-nitrosopyrimidines and amino-substituents in neighboring 4-and 6-positions.
The observed ratios of rotamers I and II in CDCl 3 are presented in Table 2 . In almost all cases, the ratio of the two rotamers was approximately 1: 1. In the case of the electron-withdrawing 3-trifluoromethylanilino group in position 6 of the pyrimidine ring, however, intramolecular hydrogen bonding between the ArNH and NO groups becomes weaker. Therefore, in the solutions of compounds 16f, 17f and 18f, the rotamers I dominate. 
Conclusions
In summary, a series of new 4-alkylamino-6-arylamino-5-nitrosopyrimidines were synthesized by treatment of various ethyl-N-alkyl-N-(6-arylamino-5-nitropyrimidin-4-yl)glycinates with sodium methoxide in methanol. In a number of these intramolecular oxidation-reduction reactions with corresponding 5-nitrosopyrimidine derivatives, the formation of 5-hydroxypteridine-6,7-diones and/or transesterification methyl-ester products were observed. In CDCl 3 solution, 4-alkylamino-6-arylamino-5-nitrosopyrimidines exist as a mixture of two rotamers.
Spectrometry (HRMS) analyses were carried out on a Dual-ESI Q-TOF 6520 (Agilent Technologies) mass spectrometer. The following abbreviations were used to identify the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, sext = sextet, br = broad.
Synthesis of ethyl-N-(6-chloro-5-nitropyrimidin-4-yl)-N-substituted glycinates (7) (8) (9) (10) To a cooled to 5 °C suspension of 4,6-dichloro-5-nitropyrimidine (6) (1.94 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL), the corresponding ethyl N-alkylglycinate (10 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 30 min. (11) (12) (13) (14) . A solution of the corresponding ethyl N- (6-chloro-5-nitropyrimidin-4-yl) -N-substituted glycinate (7-10) (1 mmol), arylamine (1 mmol), and triethylamine (0.101 g, 1 mmol) in methanol (ethanol for compounds 11f, 12f, 13f and 14f) (3 mL) was refluxed for 1 h. After cooling to room temperature, the precipitate was collected by filtration, washed with cool methanol or ethanol, then with water, and dried. If necessary, compounds were purified by crystallization or column chromatography. Ethyl-N-cyclopentyl-N-{6-[(3,4-dimethoxyphenyl) (23) . To a suspension of the corresponding ethyl-N-alkyl-N-(6-arylamino-5-nitropyrimidin-4-yl)glycinate (11-14) (0.5 mmol) in methanol (1 mL) a solution of the sodium methoxide, prepared from sodium (0.0115 g, 0.5 mmol) and methanol (1 mL), was added dropwise under stirring. The reaction mixture was stirred at room temperature for 2 h. The methanol was evaporated under reduced pressure, and the residue washed with chloroform. The resulting solid was filtered off to give the N-Isopropyl-5-nitroso-N'-(4-propyloxyphenyl)pyrimidine-4,6-diamine (15c) N-Cyclopentyl-N'-(4-ethoxyphenyl)-5-nitrosopyrimidine-4,6-diamine (17b) . Purified by column chromatography (CHCl 3 /EtOAc 7 : 1), R f 0.54, dark brown solid; yield 0.139 g (85%); mp 114-115 °C. IR (KBr, ν max , cm - 
Ethyl-N-isopropyl-N-{6-[(4-methoxyphenyl)amino]-5-nitropyrimidin-4-yl}glycinate (11a

Ethyl-N-(6-{[(3-trifluoromethyl)phenyl]amino}-5-nitropyrimidin-4-yl)-N-isopropylglycinate (11f
(2), 155.6, 130.1, 125.7, 115.1, 114.1, 63.9, 63.2, 61.6, 47.5, 29.1, 24.2, 15.1, 14.3. HRMS (ES): m/z calcd for C
Ethyl-N-cyclohexyl-N-{5-nitro-6-[(4-propyloxyphenyl)amino]-5-pyrimidin-4-yl}glycinate (14c
Ethyl-N-cyclohexyl-N-{6-[(3,4-dimethoxyphenyl)amino]-5-nitropyrimidin-4-yl}glycinate (14d
Ethyl-N-cyclohexyl-N-(6-{[(3-trifluoromethyl)phenyl]amino}-5-nitropyrimidin-4-yl)glycinate (14f
Synthesis of N-alkyl-N'-aryl-5-nitrosopyrimidine-4,6-diamines (15-18), 8-alkyl-4-arylamino-5-hydroxy-5,8-dihydropteridine-6,7-dione sodium salts (19-22) and methyl-N-(6-arylamino-5-nitropyrimidin-4-yl)-Ncyclopropylglycinates
N-(4-Ethoxyphenyl)-N'-isopropyl-5-nitrosopyrimidine-4,6-diamine (15b
, CDCl 3 ): δ C 165.7, 165.6, 162.8, 161.5, 157.5, 157.0, 146.0, 144.0, 138.9 (2), 130.2, 128.8, 125.7, 124.5, 115.2 (2), 64.0 (2), 53.3, 51.9, 33.5, 24.0 (2), 15.1 (2
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